Tolf A, Fagius J, Carlson K, et al. - In patients with multiple sclerosis (MS), researchers ascertained if treatment with autologous hematopoietic stem cell transplantation (HSCT) can result in sustained complete remission, defined as “no evidence of disease activity-4,” sustained for a period of at least 5 years without any ongoing disease-modifying treatment. This was a case series of patients with relapsing-remitting MS (n = 10) treated and followed up for 10 years at a single center between 2004 and 2007. At the end of the study, 5 out of 10 patients were in sustained complete remission. MS was resolved in three of them. According to findings, sustained complete remission after autologous HSCT for MS is feasible.